Literature DB >> 11939944

Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers.

B G H Schoser1, D Blottner, H-J Stuerenburg.   

Abstract

OBJECTIVES: To further examine the role of proteolytic enzyme expression of matrix metalloproteinases (MMP) and T-cell markers in inflammatory myopathies and controls.
MATERIAL AND METHODS: We studied the expression of MMP-2, MMP-7, and MMP-9 in 19 cases of inflammatory myopathies and controls using immunocytochemistry.
RESULTS: Inflammatory myopathies showed distinct patterns of up-regulation of MMP. MMP-9 was strongly expressed in atrophic myofibers in all inflammatory myopathies. MMP-2 immunoreactivity was similar in its distribution, however, to a weaker intensity. In dermatomyositis the perifascicular atrophy showed pronounced MMP-9 immunoreactivity, probably reflecting denervated patterns of myofibers. Moreover, MMP-7 strongly immunolabeled invaded myofibers in polymyositis cases only.
CONCLUSION: These patterns confirm, that MMP-7 up-regulation is prominent in PM, while MMP-2 immunoreactivity is only slightly elevated in inflamed muscle. In general, MMP-9 up-regulation appears to be an important additional molecular event in the multistep process of all inflammatory myopathies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939944     DOI: 10.1034/j.1600-0404.2002.1o104.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  11 in total

1.  Regulation of TIMP-2, MT1-MMP, and MMP-2 expression during C2C12 differentiation.

Authors:  Gentian Lluri; Diane M Jaworski
Journal:  Muscle Nerve       Date:  2005-10       Impact factor: 3.217

2.  Decrease of MMP-9 activity improves soleus muscle regeneration.

Authors:  Malgorzata Zimowska; Krzysztof H Olszynski; Marta Swierczynska; Wladyslawa Streminska; Maria A Ciemerych
Journal:  Tissue Eng Part A       Date:  2012-04-20       Impact factor: 3.845

3.  Matrix Metalloproteinase Responsive Delivery of Myostatin Inhibitors.

Authors:  Alexandra C Braun; Marcus Gutmann; Regina Ebert; Franz Jakob; Henning Gieseler; Tessa Lühmann; Lorenz Meinel
Journal:  Pharm Res       Date:  2016-09-14       Impact factor: 4.200

4.  Plasma matrix metalloproteinase-9 response to eccentric exercise of the elbow flexors.

Authors:  Molly C Madden; William C Byrnes; Jacob A Lebin; Matthew E Batliner; David L Allen
Journal:  Eur J Appl Physiol       Date:  2011-01-11       Impact factor: 3.078

Review 5.  Pathogenesis of idiopathic inflammatory myopathies.

Authors:  Cecilia Grundtman; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

6.  Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathway.

Authors:  Apurva K Srivastava; Xuezhong Qin; Nia Wedhas; Marc Arnush; Thomas A Linkhart; Robert B Chadwick; Ashok Kumar
Journal:  J Biol Chem       Date:  2007-09-26       Impact factor: 5.157

Review 7.  Wasting mechanisms in muscular dystrophy.

Authors:  Jonghyun Shin; Marjan M Tajrishi; Yuji Ogura; Ashok Kumar
Journal:  Int J Biochem Cell Biol       Date:  2013-05-11       Impact factor: 5.085

8.  The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.

Authors:  Yoram Nevo; Shlomit Aga-Mizrachi; Edva Elmakayes; Nurit Yanay; Keren Ettinger; Moran Elbaz; Zivia Brunschwig; Oshrat Dadush; Galit Elad-Sfadia; Roni Haklai; Yoel Kloog; Joab Chapman; Shimon Reif
Journal:  PLoS One       Date:  2011-03-22       Impact factor: 3.240

9.  A new modified animal model of myosin-induced experimental autoimmune myositis enhanced by defibrase.

Authors:  Luo Wen-Jing; Pu Chuan-Qiang; Li Hong-Hua; Lu Xiang-Hui; Liu Jie-Xiao
Journal:  Arch Med Sci       Date:  2015-12-11       Impact factor: 3.318

10.  Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ).

Authors:  Kazuhiro Fukushima; Akinori Nakamura; Hideho Ueda; Katsutoshi Yuasa; Kunihiro Yoshida; Shin'ichi Takeda; Shu-ichi Ikeda
Journal:  BMC Musculoskelet Disord       Date:  2007-06-28       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.